References
H. Lowe, D.J. McMahon, M.R. Rubin, J.P. Bilezikian, S.J. Silverberg, Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J. Clin. Endocrinol. Metab. 92, 3001–3005 (2007)
M.R. Rubin, S.J. Silverberg, Glucose intolerance and primary hyperparathyroidism: an unresolved relationship. Endocrine 42, 231–233 (2012)
I. Cakir, K. Unluhizarci, F. Tanriverdi, G. Elbuken, Z. Karaca, F. Kelestimur, Investigation of insulin resistance in patients with normocalcemic primary hyperparathyroidism. Endocrine 42, 419–422 (2012)
F. Tassone, M. Maccario, L. Gianotti, C. Baffoni, M. Pellegrino, S. Cassibba, F. Cesario, G. Magro, G. Borretta, Insulin sensitivity in normocalcaemic primary hyperparathyroidism. Endocrine 44, 812–814 (2013)
M. Procopio, M. Barale, S. Bertaina, S. Sigrist, R. Mazzetti, M. Loiacono, G. Mengozzi, E. Ghigo, M. Maccario, Cardiovascular risk and metabolic syndrome in primary hyperparathyroidism and their correlation to different clinical forms. Endocrine (2013). doi:10.1007/s12020-013-0091-z
C. Lorenzo, L.E. Wagenknecht, R.B. D’Agostino Jr, M.J. Rewers, A.J. Karter, S.M. Haffner, Insulin resistance, beta cell dysfunction, and conversion to type 2 diabetes in a multiethnic population. The ınsulin resistance atherosclerosis study. Diabetes Care 33, 67–72 (2010)
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Diri, H., Unluhizarci, K. & Kelestimur, F. Investigation of glucose intolerance in patients with normocalcemic primary hyperparathyroidism: 4-year follow-up. Endocrine 47, 971–972 (2014). https://doi.org/10.1007/s12020-014-0263-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-014-0263-5